antiviral treatment effective smallpox vaccination upon lethal monkeypox virus infection 
concern variola virus aetiological agent smallpox may used biological weapon reason several countries now stockpiling vaccinia virus-based smallpox vaccine although preventive use smallpox vaccination well documented little known efficacy used exposure virus compare effectiveness post-exposure smallpox vaccination antiviral treatment either cidofovir also called hpmpc vistide related acyclic nucleoside phosphonate analogue hpmpo-dapy lethal intratracheal infection cynomolgus monkeys macaca fascicularis monkeypox virus mpxv mpxv causes disease similar human smallpox animal model can used measure differences protective efficacies classical new-generation candidate smallpox vaccines show initiation antiviral treatment h lethal intratracheal mpxv infection using either antiviral agents applying various systemic treatment regimens resulted significantly reduced mortality reduced numbers cutaneous monkeypox lesions contrast monkeys vaccinated h mpxv infection using standard human dose currently recommended smallpox vaccine elstree-rivm significant reduction mortality observed antiviral therapy terminated days infection surviving animals virus-specific serum antibodies antiviral t lymphocytes data show adequate preparedness biological threat involving smallpox include possibility treating exposed individuals antiviral compounds cidofovir selective anti-poxvirus drugs 
